- Investor's Business Daily
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.
- Zacks
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -16% and 2.82%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of PTC Therapeutics (PTCT) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
